Addyi Cost in Connecticut 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Is Addyi and Why Does Its Cost Matter in Connecticut?

Flibanserin, sold under the brand name Addyi, is the first FDA-approved non-hormonal oral medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. Approved in August 2015, it works on serotonin receptors (5-HT1A agonist, 5-HT2A antagonist) and dopamine D4 receptors in the prefrontal cortex rather than acting on sex hormones. The mechanism is meaningfully different from testosterone-based therapies and phosphodiesterase-5 inhibitors used in other sexual dysfunction contexts.

HSDD is the most common female sexual dysfunction, affecting an estimated 8 to 10 percent of adult women in the United States at any given time, with prevalence data from the National Health and Social Life Survey suggesting even higher rates among women in their late thirties and forties. [1] Because HSDD carries real psychological and relationship burden, access to treatment is a genuine clinical concern. And in Connecticut, where retail pharmacy costs trend toward national averages, the $880 per month list price means that most patients will need an insurance, savings, or compounding strategy to make treatment sustainable.

This article covers every realistic cost pathway available to Connecticut residents in 2026: brand-name retail pricing, insurance and Medicaid coverage rules, compounded flibanserin legality, telehealth access, and manufacturer discount programs.

Brand-Name Addyi Cash Price in Connecticut in 2026

The brand-name cash price for Addyi at Connecticut retail pharmacies sits at approximately $880 per month in 2026. That figure reflects the Sprout Pharmaceuticals manufacturer list price, which has remained relatively stable since 2020. Pharmacy benefit carve-outs, dispensing fees, and specific pharmacy markups can shift the actual register price by $20 to $40 in either direction, but no meaningful generic alternative exists on the market to drive competition downward.

Sprout Pharmaceuticals is the sole manufacturer of brand Addyi. Because flibanserin's FDA approval is still protected and no AB-rated generic tablet has been approved by the FDA as of mid-2025, there is no true generic Addyi at the pharmacy counter. [2] That matters for Connecticut patients comparing drug costs across benefit tiers.

Discount aggregators such as GoodRx may show prices ranging from approximately $820 to $900 depending on which pharmacy network they access, but these figures still represent out-of-pocket costs that are prohibitive for many patients on fixed incomes or without drug coverage.

Connecticut Medicaid Coverage for Addyi

Connecticut Medicaid (HUSKY Health) covers Addyi, but prior authorization (PA) is required. The PA criteria typically ask the prescriber to document that the patient is premenopausal, that a diagnosis of HSDD has been established by a qualified clinician, and that identifiable contributing factors such as mood disorders or medication side effects have been addressed or ruled out. [3]

Clinicians prescribing Addyi in Connecticut must also be enrolled in the Addyi REMS (Risk Evaluation and Mitigation Strategy) program, which the FDA requires because of the clinically significant hypotensive interaction with alcohol. The REMS requires prescribers to counsel patients on the alcohol restriction before each prescription is issued. Pharmacies must also be REMS-enrolled to dispense Addyi. [2]

For HUSKY Health patients who meet PA criteria, the monthly cost of Addyi may drop to the applicable Medicaid co-pay tier, which is typically $3 to $4 per prescription for preferred brand drugs under Connecticut's current fee-for-service schedule. That is a substantial reduction from the $880 cash price, making Medicaid authorization the single highest-value cost-reduction pathway for eligible patients.

Patients whose PA requests are denied have the right to appeal through the HUSKY Health administrative appeals process. A prescriber's detailed letter of medical necessity that cites BEGONIA trial efficacy data and the patient's documented treatment history often strengthens an appeal.

Private Insurance Coverage of Addyi in Connecticut

Coverage of Addyi under commercial insurance in Connecticut varies by plan and formulary tier. Many large carriers either exclude Addyi entirely or place it on a specialty or non-preferred brand tier, where patient cost-sharing can range from $150 to $400 per month after deductibles. The Affordable Care Act does not mandate coverage of HSDD medications the way it mandates contraception coverage, so plan-level exclusions are legally permitted. [3]

Patients with employer-sponsored plans should request a formulary exception if Addyi is not listed or is placed on an unfavorable tier. The exception request should include the FDA-approved indication, the BEGONIA trial data, and documentation that the patient has attempted non-pharmacological interventions. The BEGONIA study (N=1,378) published in the Journal of Sexual Medicine in 2014 showed that flibanserin 100 mg at bedtime produced a statistically significant increase in the number of satisfying sexual events (SSEs) versus placebo over 24 weeks, with a mean difference of 0.49 SSEs per 28 days (P<0.001) and a significant reduction in distress scores. [4]

Some Connecticut-based insurers that use CVS Caremark or Express Scripts pharmacy benefit managers have periodically added Addyi to their covered formularies under step-therapy protocols, meaning patients must first try sex therapy or address comorbid depression before Addyi will be authorized. Confirming your specific plan's formulary status before each benefit year is recommended because tier placements change annually.

Compounded Flibanserin in Connecticut: Legality and Practicalities

Compounded flibanserin is legal in Connecticut when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. [5] The 503A designation refers to pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding of commercially available drug substances for individual patients when a valid prescription exists.

A critical regulatory nuance: the FDA considers compounding of drugs with approved commercial equivalents to be permissible for individual patients under 503A, but compounders are prohibited from manufacturing bulk quantities intended to substitute for commercially manufactured Addyi. The pharmacy must compound on a prescription-by-prescription basis.

HealthRX Compounding Evaluation Framework for Connecticut Flibanserin Patients

Before choosing a compounding pharmacy for flibanserin, Connecticut patients and their prescribers should confirm five things: (1) the pharmacy holds an active Connecticut Department of Consumer Protection pharmacy permit, (2) the pharmacy is accredited by PCAB (the Pharmacy Compounding Accreditation Board) or has passed a recent state inspection, (3) the compound is prepared as a 100 mg oral capsule or tablet matching the FDA-approved dose, (4) the prescribing clinician is enrolled in the Addyi REMS program even when the compounded form is dispensed (because the alcohol interaction risk is identical regardless of brand vs. compounded preparation), and (5) the pharmacy provides a certificate of analysis (CoA) confirming active pharmaceutical ingredient (API) identity and potency.

Cost at 503A compounding pharmacies in Connecticut can range from roughly $60 to $150 per month depending on the pharmacy's overhead, API sourcing, and dispensing volume. That represents a potential savings of $730 to $820 per month compared with the brand-name cash price. Some telehealth platforms that prescribe flibanserin have established relationships with specific compounding pharmacies and can quote an all-in cost at the time of consultation.

Telehealth Prescribing of Addyi in Connecticut

Connecticut permits telehealth prescribing of flibanserin. A prescriber licensed in Connecticut may conduct an initial evaluation via video telehealth, establish a diagnosis of HSDD, complete the required REMS counseling on the alcohol interaction, and issue a valid electronic prescription. [6] Physical examination is not required by the REMS program or by Connecticut statute for this indication.

Several national telehealth platforms active in Connecticut, including some that specialize in sexual medicine or women's health, offer flibanserin consultations. Typical consultation fees range from $49 to $149 for an initial visit. Some platforms bundle the consultation fee with the prescription cost, including access to a compounding pharmacy partner, which can make the total monthly cost substantially lower than buying brand Addyi at a retail pharmacy.

Patients should verify that their telehealth prescriber is enrolled in the Addyi REMS program. A prescriber who is not REMS-enrolled cannot legally prescribe flibanserin, regardless of whether the prescription is issued in person or via video visit.

Sprout Pharmaceuticals Savings Card and Patient Assistance in Connecticut

Sprout Pharmaceuticals offers a savings card program for commercially insured patients. Under the terms active in 2025, eligible patients with commercial (non-government) insurance may pay as little as $0 per month for the first fill and reduced co-pays on subsequent fills, subject to a monthly cap and annual maximum benefit. [7] The program is not available to patients whose primary payer is Medicaid, Medicare, or any other federal or state government health program.

Connecticut residents who are uninsured and do not qualify for Medicaid may contact Sprout's patient assistance program directly. Eligibility for free or reduced-cost medication under patient assistance is typically based on income relative to the federal poverty level and on the absence of other drug coverage. Income documentation is required.

To use the savings card at a Connecticut pharmacy, the pharmacy must be REMS-enrolled and must accept the BIN/PCN numbers on the Sprout savings card. Not every retail pharmacy in Connecticut is REMS-enrolled, so confirming enrollment before presenting the savings card avoids a dispensing refusal.

Clinical Efficacy: What the Evidence Says

The 2014 BEGONIA trial (N=1,378) remains the largest and most cited phase 3 randomized controlled trial of flibanserin 100 mg at bedtime. Published in the Journal of Sexual Medicine, it showed a statistically significant improvement in SSEs (mean increase of 0.49 per 28-day period versus placebo, P<0.001), a significant reduction in distress on the Female Sexual Distress Scale-Revised (FSDS-R), and a significant improvement in sexual desire scores on the Female Sexual Function Index (FSFI). [4]

A Cochrane systematic review of flibanserin trials concluded that the drug produces a modest but statistically significant benefit over placebo on desire and distress measures in premenopausal women with HSDD, while noting that the magnitude of effect is moderate and that side-effect profiles including dizziness, somnolence, and nausea require patient counseling. [8]

The FDA label carries a boxed warning for the combination of flibanserin with alcohol, CNS depressants, and fluconazole (a moderate-to-strong CYP3A4 inhibitor), all of which can cause severe hypotension and syncope. [2] The boxed warning is why the REMS program exists and why prescriber enrollment is non-negotiable.

The North American Menopause Society (NAMS) 2022 Position Statement on hormone therapy and sexual function notes that flibanserin is an approved pharmacological option for premenopausal women with HSDD and that the decision to use it should weigh the modest benefit against the side-effect burden and interaction profile. [9] The statement specifies: "Flibanserin is approved for the treatment of HSDD in premenopausal women and requires REMS-compliant prescribing due to the alcohol interaction risk."

How Addyi Fits Into a Broader HSDD Treatment Plan

Flibanserin is not a stand-alone cure. Multiple trials, including the 24-week DAISY study (N=1,060), showed that women who combined flibanserin with psychosocial or sex-therapy interventions reported higher satisfaction scores than those using medication alone. [10] Connecticut residents have access to certified sex therapists through the American Association of Sexuality Educators, Counselors and Therapists (AASECT) directory, and many Connecticut-based therapists offer telehealth sessions that can run concurrently with flibanserin treatment.

Hormonal evaluation is appropriate before starting flibanserin. Low estradiol due to early perimenopause or hypothalamic suppression, elevated prolactin, untreated thyroid disease, and antidepressant-related sexual dysfunction can all mimic or worsen HSDD. Correcting an underlying hormonal driver may reduce or eliminate the need for flibanserin. Connecticut-licensed endocrinologists and gynecologists can order this workup, and several telehealth platforms now offer comprehensive hormonal panels as part of a women's sexual health evaluation.

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are among the most common iatrogenic causes of low sexual desire in Connecticut's primary care population. The prescriber should review the full medication list before attributing low desire to primary HSDD. Switching from one SSRI to another or adding bupropion 150 to 300 mg/day has shown benefit in small trials (N=36 in one published series) and may be explored before flibanserin. [11]

Step-by-Step: Getting Addyi in Connecticut in 2026

Getting a flibanserin prescription in Connecticut involves a defined sequence. First, schedule an appointment with a Connecticut-licensed provider, either in person or via telehealth, who is enrolled in the Addyi REMS program. Second, complete the structured REMS counseling on the alcohol interaction, which the prescriber is required to document. Third, receive a written or electronic prescription for flibanserin 100 mg at bedtime. Fourth, bring the prescription to a REMS-enrolled pharmacy. If cost is a concern at this step, ask about the Sprout savings card (for commercially insured patients), the Medicaid PA process (for HUSKY Health enrollees), or a 503A compounding pharmacy referral.

Patients who want to minimize cost from the start should ask their telehealth or in-person provider at the initial visit whether they can route the prescription to a REMS-compliant 503A compounding pharmacy. The prescriber does not need to be affiliated with the compounding pharmacy to send the prescription there.

Allow four to six weeks from prescription issuance to first full assessment of response. The FDA label and the BEGONIA trial both used eight weeks as a meaningful efficacy checkpoint. Patients who see no meaningful benefit after eight weeks of consistent nightly dosing at 100 mg should discuss discontinuation with their prescriber rather than continuing an ineffective and expensive medication.